Michael F.Bennet

Bennet, Burr React to IOM Report: "Countering the Problem of Falsified and Substandard Drugs"

• Tweet
• Bennet%2C%20Burr%20React%20to%20IOM%20Report%3A%20%22Countering%20the%20Problem%20of%20Falsified%20and%20Substandard%20Drugs%22 ldquo The release of today rsquo s Institute of Medicine rsquo s report ldquo Countering the Problem of Falsified and Substandard Drugs rdquo calling for a national track and trace system underscores the urgency of Congress taking steps to improve the integrity of our pharmaceutical distribution supply chain for America rsquo s patients We remain committed to working with our colleagues to enact bipartisan legislation this year to put in place a uniform national traceability framework built on the principle of advancing workable traceability informed by risk based circumstances surrounding suspect and illegitimate prescription drugs rdquo ...
• 
• ldquo The release of today rsquo s Institute of Medicine rsquo s report ldquo Countering the Problem of Falsified and Substandard Drugs rdquo calling for a national track and trace system underscores the urgency of Congress taking steps to improve the integrity of our pharmaceutical distribution supply chain for America rsquo s patients We remain committed to working with our colleagues to enact bipartisan legislation this year to put in place a uniform national traceability framework built on the principle of advancing workable traceability informed by risk based circumstances surrounding suspect and illegitimate prescription drugs rdquo ...

“The release of today’s Institute of Medicine’s report “Countering the Problem of Falsified and Substandard Drugs” calling for a national track and trace system underscores the urgency of Congress taking steps to improve the integrity of our pharmaceutical distribution supply chain for America’s patients. We remain committed to working with our colleagues to enact bipartisan legislation this year to put in place a uniform, national traceability framework built on the principle of advancing workable traceability informed by risk-based circumstances surrounding suspect and illegitimate prescription drugs.”